

Special Issue

Antibody Response to Infection and Vaccination

Message from the Guest Editors

This Special Issue aims to cover experimental results, clinical studies, methods, and technology that facilitate understanding of antibody response to infection and vaccination. We are pleased to invite you to submit your studies. This Special Issue will publish original research, reviews, perspectives, and other content commissioned from leading scientists in their fields to provide expert and contextualized views of the latest research.

Research areas may include (but not be limited to) the following: antibody responses elicited by infection and by different vaccines, antibody neutralization mechanism, antibody-mediated immune pathogenicity, T-B cell interactions, antibody clonal evolution, mucosal antibody responses, broadly neutralizing antibody response, antibody immune escape by pathogens, and technologies and methods for understanding antibody responses. The emphasis is on viruses, but other pathogens, such as bacteria, fungi, and parasites, are also welcomed. We hope this Special Issue serves as a platform for researchers to exchange the latest progress in antibody response to infections and vaccinations. We look forward to receiving your contributions.

Guest Editors

Dr. Zhiqiang Ku

Institute of Molecular Medicine McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA

Dr. Xiaohua Ye

Institute of Molecular Medicine McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA

Deadline for manuscript submissions

closed (31 October 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/102346

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).